Dawson James Comments on Spring Bank Pharmaceuticals Inc’s Q2 2019 Earnings (SBPH)

Share on StockTwits

Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) – Analysts at Dawson James issued their Q2 2019 earnings per share estimates for Spring Bank Pharmaceuticals in a report issued on Monday, May 13th. Dawson James analyst R. Wasserman forecasts that the company will post earnings of ($0.52) per share for the quarter. Dawson James has a “Buy” rating on the stock. Dawson James also issued estimates for Spring Bank Pharmaceuticals’ Q3 2019 earnings at ($0.53) EPS and FY2019 earnings at ($1.92) EPS.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) last released its quarterly earnings results on Monday, April 29th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.20.

A number of other equities analysts have also recently weighed in on SBPH. Zacks Investment Research cut Spring Bank Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday. ValuEngine cut Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Cantor Fitzgerald set a $29.00 price target on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, April 12th. Finally, Chardan Capital set a $25.00 price target on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, April 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $23.80.

NASDAQ SBPH opened at $6.92 on Thursday. The firm has a market cap of $116.42 million, a PE ratio of -3.70 and a beta of 0.53. Spring Bank Pharmaceuticals has a twelve month low of $6.30 and a twelve month high of $15.00.

In other news, insider Martin J. Driscoll bought 10,000 shares of the stock in a transaction that occurred on Tuesday, April 30th. The stock was bought at an average cost of $7.34 per share, for a total transaction of $73,400.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 15.60% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN raised its position in Spring Bank Pharmaceuticals by 7.4% in the 1st quarter. Wells Fargo & Company MN now owns 21,527 shares of the company’s stock valued at $225,000 after purchasing an additional 1,484 shares in the last quarter. Northern Trust Corp raised its stake in shares of Spring Bank Pharmaceuticals by 0.9% during the fourth quarter. Northern Trust Corp now owns 171,750 shares of the company’s stock worth $1,785,000 after purchasing an additional 1,507 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Spring Bank Pharmaceuticals by 5.9% during the fourth quarter. Bank of New York Mellon Corp now owns 43,789 shares of the company’s stock worth $454,000 after purchasing an additional 2,430 shares during the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of Spring Bank Pharmaceuticals by 1,395.4% during the first quarter. BNP Paribas Arbitrage SA now owns 2,946 shares of the company’s stock worth $31,000 after purchasing an additional 2,749 shares during the last quarter. Finally, State of Wisconsin Investment Board raised its stake in shares of Spring Bank Pharmaceuticals by 30.3% during the first quarter. State of Wisconsin Investment Board now owns 18,900 shares of the company’s stock worth $198,000 after purchasing an additional 4,400 shares during the last quarter. 43.08% of the stock is currently owned by institutional investors.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV).

Featured Article: How to Trade Using Analysts Ratings

Earnings History and Estimates for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.